This work therefore reveals that BAP1 acts oncogenically in colon cancer and is a potential therapeutic target for this cancer and suggests that TG2-179-1 can be developed as a therapeutic agent for colon cancer. This evidence concerns the gene BAP1 and malignant colon neoplasm.